Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Declinol is an **over-the-counter dietary supplement** formulated to support the reduction of alcohol cravings and consumption. Its composition is based on traditional herbal and botanical compounds, including **kudzu root extract (containing daidzin)**, **gentian (bitter herb)**, **tangerine peel**, **radix bupleuri**, **rehmannia**, **licorice root**, and a **blend of B vitamins and other micronutrients**. The supplement leverages the mechanism of **daidzin from kudzu**, a **selective inhibitor of aldehyde dehydrogenase 2 (ALDH-2)**, which leads to the accumulation of acetaldehyde during alcohol metabolism, producing aversive effects that can reduce alcohol intake. Declinol also incorporates bitters that stimulate gut TAS2R receptors, thought to synergistically reduce alcohol cravings, while additional ingredients such as radix bupleuri may have neuroprotective effects, modulating neurotransmitters (endorphins, dopamine, epinephrine). The formulation uses **encapsulation technology** for enhanced bioavailability of active phytonutrients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on declinol.